Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study
James F Casella,Dana K Furstenau,Robert J Adams,Donald J Brambilla,Jeffrey D Lebensburger,James J Fehr,Lori C Jordan,Allison A King,Rebecca N Ichord,Robert C McKinstry,Michael A Kraut,Dennis W Shaw,Desiree A White,Donna A Whyte-Stewart,Radhika Avadhani,Emily A Barron-Casella,Alicia D Cannon,Cyd K Eaton,Kristin A Riekert,Joanne E Shay,Cynthia A Smith-Seidel,Diane C Weiss,Noeleen D Ostapkovich,Krista Vermillion,Kevin E Treine,Claire E Kingsbury,John J Strouse,Richard E Thompson,Daniel F Hanley
DOI: https://doi.org/10.1002/ajh.27423
2024-07-02
Abstract:Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high-quality evidence from randomized trials to estimate its neuroprotective effect is scant. HU Prevent was a randomized (1:1), double-blind, phase II feasibility/pilot trial of dose-escalated hydroxyurea vs. placebo for the primary prevention of CNS injury in children with HbSS or HbS-β0-thalassemia subtypes of SCD age 12-48 months with normal neurological examination, MRI of the brain, and cerebral blood flow velocity. We hypothesized that hydroxyurea would reduce by 50% the incidence of CNS injury. Two outcomes were compared: primary-a composite of silent cerebral infarction, elevated cerebral blood flow velocity, transient ischemic attack, or stroke; secondary-a weighted score estimating the risk of suffering the consequences of stroke (the Stroke Consequences Risk Score-SCRS), based on the same outcome events. Six participants were randomized to each group. One participant in the hydroxyurea group had a primary outcome vs. four in the placebo group (incidence rate ratio [90% CI] 0.216 [0.009, 1.66], p = .2914) (~80% reduction in the hydroxyurea group). The mean SCRS score was 0.078 (SD 0.174) in the hydroxyurea group, 0.312 (SD 0.174) in the placebo group, p = .072, below the p-value of .10 often used to justify subsequent phase III investigations. Serious adverse events related to study procedures occurred in 3/41 MRIs performed, all related to sedation. These results suggest that hydroxyurea may have profound neuroprotective effect in children with SCD and support a definitive phase III study to encourage the early use of hydroxyurea in all infants with SCD.